

Inventiva Strengthens Board of Directors with Appointment of Three Distinguished Life Sciences Leaders

Daix (France), New York City (New York, United States), July 8, 2026 – [Inventiva](#) (Euronext Paris and NASDAQ: [IVA](#)) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Dr. Barbara Krebs-Pohl, Ph.D., Dr. Anne Prener, M.D., Ph.D., and Ms. Camilla Soenderby, as independent members of its Board of Directors, effective June 30, 2026.

These appointments reflect Inventiva's commitment to assembling a Board with the depth of expertise, international reach, and strategic acumen required to guide the Company through its next phase of development. Collectively, the three directors bring leadership experience across clinical development, global commercialization, business development, and major capital transactions at leading biopharmaceutical organizations worldwide.

Mark Pruzanski, MD, Chairman of the Board, stated: “*These appointments reflect the Board's ongoing commitment to bolstering Inventiva's capacity to deliver on lanifibranor's promise as the next potential therapy to reach patients with MASH. The combined expertise that Anne, Barbara and Camilla bring will be very valuable to the company as we lay the groundwork for lanifibranor's hoped for future commercialization. On behalf of my fellow directors, I would also like to extend my sincere thanks to Annick Schwegig after her long service on the Board and recent retirement.*”

Andrew Obenshain, CEO of Inventiva, added: “*This timely expansion of the Board will help us build the foundation for what lies ahead, namely, to position lanifibranor to potentially redefine the standard of care in MASH and deliver on its promise for patients worldwide.*”

Dr. Barbara Krebs-Pohl holds a Ph.D. with a focus on antibody technologies and brings over 27 years of experience in biotechnology development, business strategy, and alliance creation. She most recently served as Chief Business Officer at MorphoSys, where she led the company's acquisition by Novartis for USD 2.9 billion and played pivotal roles in the acquisition of Constellation Pharmaceuticals by MorphoSys and the USD 1.8 billion acquisition of HI-Bio by Biogen. Dr. Krebs-Pohl currently serves as Chair of the Board of Nykode Therapeutics ASA and OneChain Immunotherapeutics, as Managing Director of the Foundation for StemCell Research and Regenerative Medicine, and as Managing Director of Viopas Venture Consulting.

Dr. Anne Prener holds an M.D. and a Ph.D. in epidemiology from the University of Copenhagen and brings more than 25 years of experience leading clinical-stage biotechnology companies through critical development and value-creation milestones. She has served as Chief Executive Officer of multiple companies, including Freeline Therapeutics, a liver-directed gene therapy company she scaled from preclinical stage to a fully integrated organization with two clinical programs and commercial-scale manufacturing, and Gyroscope Therapeutics. Earlier in her career, Dr. Prener held senior leadership roles at Baxalta and Novo Nordisk, where she was instrumental in building late-stage hematology portfolios and securing multiple product approvals in the US and EU. She has been instrumental in bringing six biologics through development, approval, and launch.

Ms. Camilla Soenderby brings 25 years of international leadership experience from executive roles at leading biopharma organizations across the EU, US, and Asia. She formerly served as a corporate officer at Takeda, where she led global portfolio commercialization and commercial excellence, overseeing global brands with annual revenue of USD 13 billion. Prior to that, she worked as SVP, Head of Global Product Strategy for Shire, having previously held regional- and general management positions at Roche Pharma, Abbott (now AbbVie) and Schering Plough (now Merck & Co), and began her career as a management consultant at McKinsey and Company. Ms. Soenderby currently serves on the Boards of Directors of BB Biotech AG, Abivax S.A. and F2G Ltd, and is a member of the Novo Advisory Group at Novo Holdings and an Industrial Advisor to EQT.

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). <https://www.inventivapharma.com>

Contacts

Media Relations

Pascaline Clerc: media@inventivapharma.com

Mark Corbae: inventivapr@icrhealthcare.com

Investor Relations

David Nikodem: IR@inventivapharma.com

Patricia L. Bank: patti.bank@icrhealthcare.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release are forward-looking statements. These statements include, but are not limited to, forecasts and estimates with respect to Inventiva’s NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH, including the quality of trial results, design, duration, timing, costs, and funding, timing of clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of lanifibranor, potential regulatory submissions, approvals and commercialization, Inventiva’s pipeline and development plans, and Inventiva’s future activities, expectations, plans, growth and prospects. Some of these statements, forecasts, and estimates may be identified by the use of words such as, without limitation, “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “estimate,” “may,” “will,” “could,” “should,” “designed,” “hope,” “target,” “potential,” “opportunity,” “possible,” “aim,” and “continue” and other similar expressions. These statements are not historical facts, but rather statements of future expectations and other forward-looking statements based on management’s beliefs. These statements reflect the opinions and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend on factors beyond Inventiva’s control. There can be no guarantee, with respect to product candidates, that clinical trial results will be available on schedule, that future clinical trials will be initiated as planned, that product candidates will receive the necessary regulatory approvals, or that the milestones planned by Inventiva or its partners will be achieved on schedule, or even at all. Future results may differ materially from the anticipated future results, performance, or achievements expressed or implied by these statements, forecasts, and estimates due to a number of factors, including the fact that interim data or data from any interim analysis of ongoing clinical trials do not predict the future results of clinical trials, the fact that the DMC’s recommendation does not preclude any eventual marketing authorization, that Inventiva cannot provide assurance on

the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on recruitment or the final impact on the results or timing of the NATiV3 trial or related regulatory issues, Inventiva is a clinical-stage company with no approved products and no historical revenue, Inventiva has incurred significant losses since its inception, Inventiva has never generated revenue from product sales, Inventiva will need additional capital to fund its operations, without which Inventiva may be required to significantly reduce its activities, delay or discontinue one or more of its research or development programs, expand its activities or capitalize on its business opportunities, and may not be able to continue as a going concern. Inventiva's ability to obtain financing and complete potential transactions on a timely basis, as well as whether, when, and to what extent dilutive instruments may be exercised and by which holders, Inventiva's future success depends on the successful clinical development, regulatory approvals, and subsequent commercialization of lanifibranor, preclinical studies or previous clinical trials are not necessarily predictive of future results, and the results of Inventiva's and its partners' clinical trials may not support Inventiva's and its partners' claims regarding product candidates, Inventiva's expectations regarding its clinical trials may prove to be incorrect, and regulatory authorities may require additional stops and/or modifications to Inventiva's clinical trials. Inventiva's expectations regarding the clinical development plan for lanifibranor for the treatment of MASH may not be realized and may not support the approval of a New Drug Application, Inventiva's ability to implement its commercialization, marketing, and manufacturing capabilities and strategy, Inventiva's ability to successfully cooperate with its existing partners or enter into new partnerships, and to fulfil its obligations under any agreements entered into in connection with such partnerships, the benefits of its current and future partnerships on the clinical development, regulatory approvals, and, if applicable, commercialization of its product candidates, as well as the achievement of milestones and timelines anticipated in connection with such partnerships, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of the applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, the recruitment and retention of patients in clinical trials is a costly and time-consuming process that could be made more difficult or impossible by multiple factors beyond the control of Inventiva and its partners, Inventiva's product candidates may cause adverse reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces significant competition, and Inventiva's activities, preclinical studies, and clinical development programs, as well as timelines, Inventiva's financial condition and results of operations could be materially and adversely affected by changes in laws and regulations, adverse conditions in its industry, geopolitical events, such as the conflict between Russia and Ukraine and the resulting sanctions, the conflict in the Middle East and the related risk of a wider conflict and ongoing conflicts, epidemics, and macroeconomic conditions, including changes in international trade policies, global inflation, fluctuations in financial and credit markets, customs duties and other trade barriers, political unrest and natural disasters, uncertain financial markets, and disruptions in banking systems. In light of these risks and uncertainties, no representation is made as to the accuracy or completeness of these forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts, and estimates are only valid as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2025 filed with the Autorité des Marchés Financiers on April 8, 2026, and the Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on April 8, 2026 for other risks and uncertainties affecting Inventiva, including those described under the caption "Risk Factors", and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.